Authors
Loading...
Retrospective cohort study details dosing patterns and vial use of elranatamab in multiple myeloma patients, indicating common outpatient administration post-approval.
Johnson et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: